SCHEMBL762912

SCHEMBL762912

CC(C)(C)OC(=O)N1CC(=O)c2cn(S(=O)(=O)c3ccccc3)c3cccc(c23)C1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 9/20 0.54
MAPK1 P28482 1/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
BCHE P06276 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CA12 O43570 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TGFBR1 P36897 1/20 0.37
HTR3A P46098 1/20 0.37
RORC P51449 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL740874 0.85 HTR6 (0.48) HTR6MEN1KMT2ACYP3A4CYP2D6
SCHEMBL17369314 0.74 MAPK1 (0.54) MAPK1DDB1CRBNNAMPT
SCHEMBL29813840 0.74 MAPK1 (0.54) MAPK1DDB1CRBNNAMPT
SCHEMBL741574 0.73 HTR6 (0.51) HTR6CYP3A4CYP2D6CA12CA2
Trifluoroacetic Acid SCHEMBL740840 0.73 HTR6 (0.44) HTR6LMNASMN1; SMN2HTR3A
SCHEMBL5698323 0.72 HTR6 (0.54) HTR6BCHETGFBR1
SCHEMBL762909 0.70 CRBN (0.47) MAPK1DDB1CRBNMEN1KMT2A
SCHEMBL29676965 0.70 MAPK1 (0.64) MAPK1DDB1CRBNNAMPT
SCHEMBL5183098 0.70 MAPK1 (0.64) MAPK1DDB1CRBNNAMPT
SCHEMBL21257533 0.70 USP9X (0.46) HTR6MAPK1TGFBR1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138333-B2 Sulfonyl-indole derivatives PROXIMAGEN LIMITED (GB) 2012-03-20 US disclosed
US-8138333-B2 Sulfonyl-indole derivatives PROXIMAGEN LIMITED (GB) 2012-03-20 US disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 US disclosed
US-20080293694-A1 New compounds BIOVITRUM AB (PUBL.) (SE) 2008-11-27 US disclosed
WO-2008110598-A1 TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY BIOVITRUM AB (PUBL) (SE) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293694-A1 New compounds HTR6, HTR1A, HTR1B HTR6 1/4885MAPK1 1974/4885DDB1 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.